Hemab ApS
Core data
Name | Hemab ApS |
Address | Nordre Fasanvej 215, 2000, Frederiksberg |
Founded | Sep 27, 2019 |
| 46 / 45 | |
Locations (P-units) | 1View locations |
Website | https://www.hemab.com/ |
 Instagram | @hemab_therapeutics |
 LinkedIn | hemabaps |
Branch | Fremstilling af farmaceutiske præparater (212000) |
Name | Hemab ApS |
Address | Nordre Fasanvej 215, 2000, Frederiksberg |
Founded | Sep 27, 2019 |
| 46 / 45 | |
Locations (P-units) | 1View locations |
Website | https://www.hemab.com/ |
| Instagram | @hemab_therapeutics |
| LinkedIn | hemabaps |
Branch | Fremstilling af farmaceutiske præparater (212000) |
Keep track of Hemab ApS
Description
Hemab develops targeted therapies for serious bleeding disorders, with a focus on conditions underserved by existing treatment options.
Hemab develops therapies for blood coagulation disorders, including researching treatment approaches intended to prevent bleeding and improve disease management.
Company's own description on virk.dk
Hemab is a clinical-stage biotechnology company developing therapies that reimagine the treatment of blood coagulation disorders to sustain life and human resilience. Based in Denmark and the United States, Hemab's mission is to build the leading coagulation company by discovering, developing, and commercializing innovative therapies for the millions of patients worldwide suffering from serious bleeding and thrombotic diseases, including Glanzmann thrombasthenia, Factor VII deficiency, Von Willebrand Disease and other conditions of abnormal bleeding, all of which can cause significant life-long burden to patients. Hemab's assets address critical gaps in the treatment of coagulation disorders.
Products & services
Therapies for blood coagulation disorders · Therapeutic product candidates and clinical research programs · Natural history studies
Industries
Biotechnology · Therapeutics development · Blood coagulation disorders
Customer types
Patients with serious bleeding disorders · Healthcare professionals · Potential clinical investigators
Financials
| Reporting period | 2025USD | |||
|---|---|---|---|---|
| Profit before tax | -62,380,000 | |||
| Net income | -61,353,000 | |||
| Total assets | 195,363,000 | |||
| Equity | 183,422,000 | |||
| Avg. employees | 54 | |||
2022–2025 Unlock financial history | ||||
Datapublica Risk Score
What goes into the assessment
Financials
Equity ratio, profitability, and liquidity
Accounts and history
Late filings and previous financial distress
Owners and management
Past bankruptcies and owners’ other companies
Company and connections
Age, industry, and shared addresses or contact details
Standard: Score and risk bandPro: Also a detailed explanation of the factors
Contact
No contact details have been registered for this company.
Gazelle
Loading gazelle status…
Børsen Gazelle is Dagbladet Børsen's award. Datapublica is not affiliated with Børsen. Calculated statuses are Datapublica's own analysis of public CVR financial-statement data.
People
| Person | Roles | Titles |
|---|---|---|
| Benny Sørensen | Roles BoardManagement | TitlesBESTYRELSESMEDLEM • ADM. DIR. |
| Mads Nikolaj Behrndt-Eriksen | Roles Management | TitlesDIREKTØR |
Auditor
| Audit firm | Auditor | Role | From |
|---|---|---|---|
| EY | AuditorChristian Schwenn Johansen | RoleState Authorised Public Accountant | FromJun 30, 2026 |
| — | AuditorMads Obel Knøsgaard | RoleState Authorised Public Accountant | FromJun 30, 2026 |
Legal owners
| Owner | Ownership | Voting rights | From |
|---|---|---|---|
Foreign legal entity | Ownership100 % | Voting rights100 % | FromMar 30, 2026 |
Ultimate owners
| Name | Ownership through | Calculated ownership |
|---|---|---|
| 🇺🇸Hemab Therapeutics Holdings, Inc. | Ownership through Direct | 100 % |